A recent study on a single patient with NSCLC has shown that crizotinib-resistant ALK-positive cells can be resensitized to crizotinib after treatment with loratinib via acquiring ALK L1198F mutation [31]. Here, ALK is linked to non-small cell lung carcinoma.